MedTrace Logo

Beta Cell Relieving and Cardiovascular Protective Effects of LANTUS Treatment in Type 2 Diabetes Patients

NCT01206712 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 106

Last updated 2010-09-22

No results posted yet for this study

Summary

The purpose of this phase IV clinical trial is to investigate the effect of Insulin glargine + metformin treatment vs. sulfonylurea + metformin treatment vs. DPP-4 + metformin treatment vs. healthy volunteers on ß-cell function after the uptake of a standardized meal.

Conditions

  • Diabetes Mellitus, Type 2

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • IKFE Institute for Clinical Research and Development

    collaborator OTHER

  • ikfe-CRO GmbH

    lead INDUSTRY

Principal Investigators

  • Thomas Forst, Prof. MD · IKFE Institute for Clinical Research and Development

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01206712 on ClinicalTrials.gov